4-Star Stocks Poised to Pop: Amgen

Before you go, we thought you'd like these...
Before you go close icon

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotech giant Amgen (NAS: AMGN) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Amgen's business and see what CAPS investors are saying about the stock right now.

Amgen facts

Headquarters (founded)Thousand Oaks, Calif. (1980)
Market Cap$54.0 billion
IndustryBiotechnology
Trailing-12-Month Revenue$15.6 billion
ManagementChairman/CEO Kevin Sharer (since 2000)
COO Robert Bradway (since 2010)
Return on Equity (average, past 3 years)19.4%
Cash/Debt$20.6 billion / $21.4 billion
Dividend Yield2.1%
CompetitorsJohnson & Johnson
Novartis AG
Sanofi

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 92% of the 2,129 members who have rated Amgen believe the stock will outperform the S&P 500 going forward.  

Earlier this month, one of those Fools, All-Star Staka, weighed the stock's pros and cons for our community:

Positive:
- Cash generator
- High margins
- Pays a dividend (just introduced it)
- Biotech might be the next big growth story (over the coming decade) although I'm not sure if Amgen will be an important part of this story

Negative:
- Slow growth
- Huge debt
- Insiders sell everything they are allowed to sell at the moment they get it

If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite a strong four-star rating, Amgen may not be your top choice.

We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2012." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the newTrackPoisedToCAPS account.

At the time this article was published Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson and Novartis, as well as creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days.We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners